JP2009298740A - Composition for ameliorating cognitive motor function - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a drug or a nutritional supplement which improves a visual cognitive motor function disorder, in other words, improves visual cognition and the quality of responsive motion thereto, enhances the accuracy and the attentiveness in the activity of a healthy subject, inhibits the deterioration of the speed and the quality of the responsive motion of a person decreased in the visual cognitive motor function, prevents cognitive fatigue affecting the mood as well and the like, particularly in healthy children, the young, the middle-aged and/or the elderly, and improves the factor relating thereto. <P>SOLUTION: A remarkable improvement, prevention, and recovery effect of the visual cognitive motor function disorder can be brought about by taking in a composition comprising xanthophyll. <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

  The present invention relates to a composition having an effect of improving / improving visual motor function using xanthophyll as an active ingredient. Furthermore, it is related with the composition which has the improvement effect of the improvement / improvement effect of visual movement function which contains astaxanthin as an active ingredient. Moreover, it is related with the pharmaceutical and foodstuffs and functional food which consist of a composition which has the improvement and improvement effect of visual movement function.

  Humans have the ability to recognize the situation of the external environment and one's own situation, judge the current situation, predict the future situation, and respond to the body's movements and movements (recognition movement function) . This is in demand for exercises that require instantaneous judgment, particularly ball games, martial arts, and video games. In driving a car or the like, it is necessary for safety to recognize the position and speed of a pedestrian or another car and perform the driving in an instant. The cognitive motor function senses the current situation from the sensory organs such as the eyes and ears, recognizes and judges with the brain, imagines the future situation, issues instructions to each part of the body, and moves the body. Cognitive motor function declines due to aging, fatigue, illness, and damage.

  Xanthophyll has excellent antioxidant ability among carotenoids, especially astaxanthin is shellfish such as shrimp and crab, fish such as salmon and Thailand, algae such as green alga Hematococcus, yeasts such as red yeast Phaffia, etc. And is used as a red pigment, and has been found to have an antioxidant action about 1000 times that of vitamin E and about 40 times that of β-carotene.

  As an effect of improving the physical function of astaxanthin, an effect of improving the muscle duration (Patent Document 1), an effect of improving the eye regulation function (Patent Document 2), an effect of improving fatigue (Patent Document 3) and the like are known. . In addition, it is known that there is an effect only on visual functions such as improvement of visual acuity mainly composed of astaxanthin and anthocyanin, and a sensitive effect of optic nerve function (Patent Document 4).

However, it is known that xanthophyll, especially astaxanthin, has the effect of improving and improving the recognition of the external environment, which is a series of movements of recognition-cognition-judgment-prediction-motion, and the corresponding physical movement / behavior (cognitive motor ability) It has not been done.
International publication WO99 / 11251 pamphlet International Publication WO02 / 94253 pamphlet Japanese Unexamined Patent Publication No. 2006-347927 Japanese Laid-Open Patent Publication No. 2008-35714

  Recognize the situation of the external environment and one's own situation, judge the current situation, predict the future situation, and improve the function (recognition movement function) of performing body movement / exercise in response, and the disease and injury It aims at providing the composition which has the improvement effect of the cognitive motor function reduced by causes, such as aging, and the pharmaceutical, functional food, and food / beverage products containing the composition.

  As a result of intensive studies to achieve the above object, the present inventor has found that xanthophyll, particularly astaxanthin, has an excellent action for improving and improving cognitive motor dysfunction, and has completed the present invention.

That is, the present invention has the following configuration.
(1) A composition for improving and improving cognitive motor function comprising xanthophyll.
(2) The composition according to (1), containing 2 to 100 mg of xanthophyll.
(3) The composition according to any one of (1) to (2), wherein the mixing ratio of xanthophyll and fatty acid glyceride is 4 to 30:40 to 90.
(4) The composition according to any one of (1) to (3), wherein the xanthophyll is astaxanthin.
(5) The composition according to any one of (1) to (4), wherein the recognition is based on visual recognition.
(6) Food and drink, functional food, and pharmaceutical comprising the composition according to any one of (1) to (5).
(7) A method for using xanthophyll for producing the composition for improving and improving cognitive motor function according to any one of (1) to (5).

  By administering and ingesting a composition comprising xanthophyll, particularly astaxanthin, in the form of pharmaceuticals, functional foods, foods and drinks, it is possible to improve cognitive motor dysfunction due to illness or fatigue or to improve cognitive motor function.

The xanthophyll according to the present invention will be described.
In the present invention, xanthophylls are astaxanthin, zeaxanthin, lutein, cryptoxanthine, tunaxanthin, salmoxanthine, parasiloxanetin, violaxanthin, anteraxanthin, cucurbitaxanthin, diatoxanthine, alloxanthin, pectinol, pectinolone, and mactra. Xanthine, capsanthin, capsanthinol, fucoxanthin, fucoxanthinol, peridinin, halocinthiaxanthine, amaranthiaxanthine, canthaxanthin, echinone, rhodoxanthine, bixin, norbixin, preferably astaxanthin, cryptoxanthin, zeaxanthin , Lutein, canthaxanthin, capsanthin, fucoxanthin, most preferably xanthophyll It is astaxanthin because antioxidant capacity is high. As these xanthophylls, those extracted from natural products such as plants, animals, microorganisms, and chemically synthesized products can be used. Extracts of substances from natural products are not particularly limited in terms of raw material type, production area and production method.

  In the description of the present invention, xanthophyll includes xanthophyll and / or its ester unless otherwise specified. Furthermore, the ester of xanthophyll includes a monoester form and / or a diester form.

  As the xanthophyll of the present invention, at least one of xanthophyll free form, monoester form and diester form can be used. Diesters are chemically and physically more stable than free and monoesters because two hydroxyl groups are protected by ester bonds, and are less susceptible to oxidative degradation in the composition of the present invention. However, it is considered that when it is taken into the intestine by an enzyme or into a living body, it is rapidly hydrolyzed to xanthophyll by the in vivo enzyme and exhibits an effect.

  Examples of the monoester of xanthophyll include esters esterified with lower or higher saturated fatty acids or lower or higher unsaturated fatty acids. Specific examples of the lower or higher saturated fatty acid or the lower or higher unsaturated fatty acid include acetic acid, lauric acid, myristic acid, pentadecanoic acid, palmitic acid, palmitooleic acid, hebutadecanoic acid, elaidic acid, ricinoleic acid, and betrothelin. Acid, vaccenic acid, eleostearic acid, punicic acid, ricinic acid, parinaric acid, gadoric acid, 5-eicosenoic acid, 5-docosenoic acid, cetoleic acid, erucic acid, 5,13-docosadienoic acid, ceracholic acid, decenoic acid , Stering acid, dodecenoic acid, oleic acid, stearic acid, eicosaopentaenoic acid, docosahexaenoic acid, linoleic acid, linolenic acid, arachidonic acid and the like. Examples of carotenoid diesters include diesters esterified with the same or different fatty acids selected from the group consisting of the above fatty acids.

  Furthermore, monoesters of xanthophyll include amino acids such as glycine and alanine; monovalent or polyvalent carboxylic acids such as acetic acid and citric acid; inorganic acids such as phosphoric acid and sulfuric acid; sugars such as glucoside; glycerosugar fatty acids and sphingosaccharides. Examples thereof include sugar esters such as fatty acids; fatty acids such as glycero fatty acids; monoesters esterified with glycerophosphoric acid and the like. In addition, the salt of the said monoester is also included when it can be considered. Examples of fatty acid derivatives include phospholipid type, alcohol type, ether type, sucrose ester type and polyglycerin ester type of the above fatty acids.

  As the diester of xanthophyll, the group consisting of the lower saturated fatty acid, higher saturated fatty acid, lower unsaturated fatty acid, higher unsaturated fatty acid, amino acid, mono- or polyvalent carboxylic acid, inorganic acid, sugar, sugar fatty acid, fatty acid and glycerophosphoric acid And diesters esterified with the same or different acids selected from In addition, the salt of the said diester is also included when it can be considered. Examples of the diester of glycerophosphoric acid include saturated fatty acid esters of glycerophosphoric acid, or glycerophosphoric acid esters containing fatty acids selected from higher unsaturated fatty acids, unsaturated fatty acids or saturated fatty acids.

  Astaxanthin means a product derived from a natural product or obtained by synthesis. Examples of those derived from natural products include microalgae such as the green alga Hematococcus, yeasts such as the red yeast Phaffia, crustacean crustaceans such as shrimp, krill, crab, and craniopod viscera such as squid and octopus Adonis genus petals such as seafood skins and fins of seafood, alpha-proteobacteria such as Paracoccus sp. N81106, Brevundimonas sp. SD212, Erythrobacter sp. PC6, and Gordonia sp. KANMONKAZ-1129 Examples thereof include those obtained from fungi, Labyrinthulas such as Schizophytriuym sp. KH105 (especially Yabetaceae) and astaxanthin-producing genetically modified organisms. Natural extracts and chemically synthesized products are commercially available and are readily available.

  Astaxanthin is 3,3′-dihydroxy-β, β-carotene-4, 4′-dione and has stereoisomers. Specifically, three stereoisomers of (3R, 3′R) -astaxanthin, (3R, 3 ′S) -astaxanthin and (3S, 3 ′S) -astaxanthin are known. Any of these can be used. The present invention includes monoesters and diesters of these astaxanthin isomers.

  In the present invention, the fatty acid ester of astaxanthin may be any of those derived from natural products or those obtained by synthesis, but those derived from natural products in which astaxanthin esters are dissolved in various oils and fats are preferred from absorption in the body. Natural sources include, for example, krill extract, faffia yeast extract, and haematococcus algal extract, but particularly preferred is hematococcus alga extract depending on the stability of astaxanthin and the type of ester of astaxanthin. .

  Fatty acid esters of astaxanthin have not been observed to be mutagenic, are known to be highly safe compounds, and are widely used as food additives (Jiro Takahashi et al .: Toxicity test of hematococcus alga astaxanthin-Ames Test, rat single dose toxicity test, rat 90 day repeated oral dose toxicity test, clinical medicine, 20: 867-881, 2004).

  Haematococcus algae is a green algae belonging to the Volboxic Chlamydomonas family, and since it is a green algae, it has a high chlorophyll content and is green, and it swims in the water with two flagella, but it lacks nutrient sources, changes in temperature, etc. Under starvation conditions, dormant spores are formed, the astaxanthin content is increased, and red spheres are formed. In the present invention, Haematococcus algae in any state can be used, but it is preferable to use Haematococcus algae that have become dormant spores containing a large amount of astaxanthin. In addition, among green algae belonging to the genus Haematococcus, for example, Haematococcus pluvialis is preferable.

  As a method for culturing Haematococcus green algae, a hermetically sealed culture method is preferred in which no foreign microorganisms are mixed and propagated and other contaminants are not mixed. For example, a partially open-type dome shape, conical shape or cylindrical shape is preferable. A culture method using a culture medium having a culture apparatus and a gas discharge device movable within the apparatus (International Publication No. 99/50384), or culturing by irradiating light from inside a sealed culture apparatus And a method using a flat culture tank or a tube-type culture layer are suitable.

  The method for obtaining an extract from Haematococcus algae according to the present invention includes a method in which Haematococcus algae is dried and pulverized and then extracted with an organic solvent such as acetone or alcohol, and the Haematococcus algae is suspended in an organic solvent and pulverized and extracted simultaneously. Or a supercritical extraction method using carbon dioxide or the like.

  The supercritical extraction method can be performed by a conventional method. For example, Hirose (Ind Eng Chem Res, 2006, 45 (10), 3652-3657, Extraction of Astaxanthin from Haematococcus pluvialis Using Supercritical CO2 and Ethanol as Entrainer) Can be done by the method.

  Various methods are known for extracting and purifying the culture or the crustacean using an organic solvent. For example, since astaxanthin and its esters are oil-soluble substances, astaxanthin-containing components can be extracted from natural products containing astaxanthin with an oil-soluble organic solvent such as acetone, alcohol, ethyl acetate, benzene, and chloroform. Also, supercritical extraction can be performed using carbon dioxide, water, or the like. After extraction, the solvent is removed according to a conventional method to obtain a mixed concentrate of monoester type astaxanthin and diester type astaxanthin. The obtained concentrate can be further purified by separation column or lipase decomposition, if desired.

  A method of drying Haematococcus algae cultured in the above-mentioned dome type culture apparatus or closed type culture apparatus, extracting with acetone after pulverization, or performing pulverization and extraction in acetone at the same time, and then removing acetone to extract astaxanthin However, as a result of purifying after purifying by supercritical extraction, there is almost no oxidation of astaxanthin because there is no contact with air, there are few impurities, that is, there are few substances that inhibit the effect of the present invention, and astaxanthin and triglyceride are contained. It can be contained in a large amount with good purity, which is preferable.

  The amount of astaxanthin used in the cognitive motor function improving / enhancing composition of the present invention is an astaxanthin free form equivalent amount, and is an oral dose of 0.01 to 100 mg, preferably 0.1 to 20 mg per day for adults. Dosing or parenteral administration. The dose varies depending on the age, weight, symptom level, and dosage form of the person taking the drug. The amount of astaxanthin in the composition of the present invention can be contained in an amount of 0.01 to 99% by weight, preferably 0.1 to 90% by weight.

  The dose (intake) that can be immediately experienced by the composition for improving and improving the cognitive motor function of the present invention is an amount that is difficult to take in the form of normal food, and astaxanthin per day for each adult human. Is 6 mg or more. Below this, it is more effective for long-term use. These may be divided into a plurality of times such as for each meal to make the daily intake.

  Cognitive motor function improvement / improvement in the present invention refers to recognition ability in the cranial nervous system and ability to judge recognized information in the brain (judgment ability) due to a cause such as disorder, disease, fatigue, aging, etc. It is to improve the state in which the ability to send movements to the body (sending ability) is reduced, and to improve the ability of a healthy person to recognize, judge and send. Here, the recognition means that the eye does not adjust the image by adjusting the focus but identifies and confirms the image data obtained by the eye with the visual part in the brain.

  In the present invention, the recognition motor function improvement / improvement effect includes improvement, treatment and prevention of cognitive motor dysfunction, and improvement of cognitive motor function. The external recognition sensation is visual recognition. However, the present invention is not limited to this. In addition to vision, recognition by senses such as hearing, smell, taste, and pain is also included.

  The composition for improving / improving cognitive motor function of the present invention has the effect of preventing, improving, treating, or improving the normal response and impairment of cognitive ability, judgment ability and transmission ability. It has the effect of improving the recognition and movement of external situations such as sports that require prevention, improvement, treatment of diseases and injuries such as dementia, and quick response such as ball games and martial arts. For example, improved batting rate in baseball, improved avoidance and counter in boxing, improved operation in car racing, improved avoidance, hitting and shooting in video games, improved rotation display in pachinko and slot machines, etc. effective.

  When the composition for improving cognitive motor function of the present invention is used, it can be used in the form of ordinary foods and beverages and pharmaceuticals. Hereinafter, as specific examples of xanthophyll, astaxanthin will be described, but the present invention is not limited thereto.

  In order to assist the visual reaction movement improving effect of the present invention, a substance having an assisting effect can be added. For example, vitamins A; carotenoids (excluding xanthophyll); vitamins B; vitamins C; vitamins D, vitamins E; tocotrienols; glutathione and derivatives thereof and salts thereof; catechins, anthocyanins, tannins, rutins, Polyphenols such as isoflavone, chlorogenic acid, ellagic acid, curcumin, coumarin; linoleic acid, α- or γ-linolenic acid, arachidonic acid, eicosapentaenoic acid, succinic acid, docosahexaenoic acid and their derivatives and salts thereof; collagen, elastin , Fibronectin, keratin proteins and their derivatives and hydrolysates; α-hydroxy acids such as glycolic acid, lactic acid, malic acid, citric acid, salicylic acid and their derivatives and their salts; serum deproteinization , Spleen, placenta, chicken crown, royal jelly, yeast, lactic acid bacteria, bifidobacteria, ganoderma, carrot, assembly, rosemary, buckwheat, garlic, hinokitiol, cephalanthin, aloe, salvia, arnica, chamomile, birch, hypericum, eucalyptus, mugwort, Natural products such as Sempukuka, Caquette, Sunpens, Sakuhakuhi, Toki, Ibukitorano, Clara, Hawthorn, Shirayuri, Hops, Neubara, Yokuinin, Dokudami, Seaweed, Natto, Lemongrass, Hibiscus and their extracts; adenosine triphosphate, Adenylic acid derivatives such as adenosine diphosphate and adenosine monophosphate; minerals such as iron, vanadium, molybdenum, manganese, copper, potassium, magnesium, calcium, zinc, selenium, iodine; mannitol, Monosaccharides such as sitolitol and glucosamine; polysaccharides such as hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, keratan sulfate, glycogen, chitin and chitosan; nucleic acids such as deoxyribonucleic acid and ribonucleic acid; other glycyrrhizic acid, One or more kinds can be selected from the group consisting of guanine, mucin, ubiquinone, α-lipoic acid, octacosanol, allicin, alliin, and the like, and mixtures thereof. These components are generally blended in an amount of 0.01 to 90% by weight, preferably 0.1 to 50% by weight, based on the total amount of the pharmaceutical, and can be used in combination of one or more.

  The pharmaceutical agent containing the composition for improving visual reaction motor dysfunction of the present invention can be administered orally. Examples of oral dosage forms include solid dosage forms such as tablets, intraoral quick disintegrating tablets, capsules, granules and fine granules, and liquid dosage forms such as syrups and suspensions. Pharmaceutical products include quasi-drugs.

  The pharmaceutical comprising the composition for improving visual reaction motor dysfunction of the present invention may contain an appropriate amount of various additives used for the production of general preparations. Examples of such additives include excipients, binders, acidulants, foaming agents, artificial sweeteners, fragrances, lubricants, colorants, stabilizers, pH adjusters, and surfactants. Examples of excipients include corn starch, potato starch, wheat starch, rice starch, partially pregelatinized starch, pregelatinized starch, and starches such as porous starch, sugars such as lactose, sucrose, and glucose, mannitol, xylitol, Sugar alcohols such as erythritol, sorbitol, maltitol, magnesium aluminate metasilicate (product name "Neusilin" manufactured by Fuji Chemical Industry Co., Ltd.), hydrotalcite, anhydrous calcium phosphate [product name "Fujicalin", Fuji Chemical Industry Co., Ltd. )], Inorganic compounds such as precipitated calcium carbonate, calcium silicate, and light anhydrous silicic acid. Examples of the binder include hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, gum arabic powder, gelatin, and pullulan. Disintegrants include, for example, starch, agar, carmellose calcium, carboxymethyl starch sodium, croscarmellose sodium, crospovidone, crystalline cellulose, FM astaxanthin, and a powdered state for better absorption and formulation of peptides. Can be. ELT [Trademark, manufactured by Fuji Chemical Industry Co., Ltd.]. Examples of sour agents include citric acid, tartaric acid, malic acid, ascorbic acid and the like. Examples of the foaming agent include sodium bicarbonate and sodium carbonate. Examples of the sweetener include saccharin sodium, dipotassium glycyrrhizin, aspartame, stevia and thaumatin. Examples of the fragrances include lemon oil, orange oil, menthol and the like. Examples of the lubricant include magnesium stearate, sucrose fatty acid ester, polyethylene glycol, talc, stearic acid, and sodium stearyl fumarate. Examples of the colorant include edible pigments such as edible yellow No. 5, edible red No. 2, and edible blue No. 2, edible lake pigments, and iron sesquioxide. Examples of the stabilizer include sodium edetate, tocopherol, cyclodextrin and the like. Examples of the pH adjuster include citrate, phosphate, carbonate, tartrate, fumarate, acetate, amino acid salt and the like. Examples of the surfactant include polysorbate 80, methyl cellulose, hydroxyethyl cellulose, sodium carboxymethyl cellulose, polyoxyethylene sorbitan monolaurate, gum arabic, and powdered tragacanth. In order to better absorb and formulate astaxanthin and peptides, it can be in a powder state.

  The composition of this invention can be mix | blended and used for food-drinks and feed, and can acquire the effect similar to a pharmaceutical.

  As foods and beverages, supplements, functional health foods, and special-purpose foods are preferred because they can be used as supplements, functional health foods, special-purpose foods, and general foods, and the ease of intake and intake are easy to determine. It can be ingested in the same form, solid dosage forms such as tablets, buccal disintegrating tablets, capsules, granules, fine granules, and liquid dosage forms such as syrups and suspensions. In addition to the ingredients used in the above pharmaceutical preparations, those that can be used in foods can be selected. Besides, milk protein, soy protein, egg albumin protein, etc., or egg white oligopeptides, soy hydrolysates that are degradation products thereof, A mixture of amino acids alone can also be used in combination. In addition, when provided in the form of a drink, nutritional additives such as amino acids, vitamins and minerals, sweeteners, spices, fragrances, and pigments may be added to improve the nutritional balance and flavor during intake. Good. The form of the food or drink of the present invention is not limited to these.

  In the present invention, foods and beverages permitted to improve or prevent symptoms are foods having medicinal effects that are permitted or designated by the government or public organizations, such as nutritional functional foods and foods for specified health use. Such as health functional foods, special purpose foods, etc. Although names and rules vary depending on circumstances, times, and systems in each country, those that are essentially the same are included in the present invention.

  Examples of forms of general foods, that is, foods and drinks include margarine, butter, butter sauce, cheese, fresh cream, shortening, lard, ice cream, yogurt, dairy products, sauce meat products, fish products, pickles, french fries, potato chips , Snacks, kakimochi, popcorn, sprinkles, chewing gum, chocolate, pudding, jelly, gummy candy, candy, drop, caramel, bread, castella, cake, donuts, biscuits, cookies, crackers, macaroni, pasta, ramen, buckwheat, udon , Salad oil, instant soup, dressing, eggs, mayonnaise, miso, etc., or carbonated or non-carbonated beverages such as fruit juices, soft drinks, sports beverages, non-alcohol or liquor such as tea, coffee, cocoa Yuru, it can be added to examples of the general foods such as alcoholic beverages, such as medicinal liquor.

  In food and drink, astaxanthin and peptides are blended together with raw materials for general foods, and are manufactured by processing according to conventional methods. The amount of astaxanthin and peptide varies depending on the form of the food and is not particularly limited. In general, the amount of astaxanthin and peptide used can be appropriately selected by those skilled in the art according to the type of food and drink, and the amount described above is blended. can do.

  Even when the regulatory function improving composition of the present invention is blended in a feed, it is possible to obtain the same effects as pharmaceuticals and foods and drinks, for example, rats, rabbits, monkeys, dogs, cats, pigs, cows, sheep, horses, Can be administered to lizards, frogs, crocodiles, fish.

  The feed of the present invention is in the form of a solid preparation, solid, pellet, granule, biscuit, kneaded, etc., and dry food, semi-dry food (for example, feed having a water content of about 10 to 50% by weight), or wet such as canned food It is not particularly limited to food (for example, feed having a water content of about 50 to 80% by weight). Astaxanthin and peptide can be added to and mixed with the feed material or mixed with an aqueous solution of astaxanthin and peptide by a suitable process in the process of conventional feed production. Also, like human dietary supplements, it should be manufactured with solid preparations such as tablets, sublingual tablets, pills, powders, powders, fine granules, granules, capsules and soft capsules that are easy to ingest. Can do.

  There are no particular restrictions on the ingredients that can be used as long as they can be used as feed, but feed ingredients may vary depending on the type of feed such as conventional ingredients such as fish meal, fish, seafood, fishmeal, and livestock meat. Animal raw materials such as meat powder, meat and bone meal, blood meal, feather meal, cocoon oil cake, skim milk powder, animal fats (beef oil, pork oil, bone oil, etc.), eggs, milk, etc .; beer yeast, torula yeast, etc. Microorganisms; corn, milo, wheat, barley, rye, oats, wheat flour, brown rice, millet, soybeans, quinaco, cassava and other cereals; pregelatinized starch, starches such as starch; soybean oil cake, molted soybean oil cake, rapeseed oil cake, Oil pods such as peanut oil coconut, palm oil cocoon, sunflower oil cocoon, linseed oil cocoon, sesame oil cocoon, safflower oil cocoon, palm kernel oil cocoon, kapok oil cocoon; rice bran, barley bran, bran Nuka's; Gurung feed, gluten meal, starch cake, honey, soy sauce cake, beer cake, beet pulp, bagasse, tofu cake, malt root, citrus peel, tangerine juice cake, etc .; alfalfa meal, timothy hay, Fibrin such as koji; excipients, binders, disintegrants, saccharides such as salt and sugar, vitamins, amino acids, minerals and other components can be used alone or in combination.

  As a raw material which can be blended in a solid preparation, in addition to the above-mentioned raw materials, for example, it can be produced by uniformly mixing with a carrier generally used in the human food field. Specifically, sugars such as sucrose, sorbitol and fructose, glycols such as polyethylene glycol and propylene glycol, oils such as sesame oil, rapeseed oil, olive oil and soybean oil, and flavors such as strawberry flavor and peppermint Can be manufactured using. Also in the form of powders, pills, capsules, soft capsules, tablets, excipients such as lactose, glycolose, sucrose, lactose, mannitol, corn starch, silicon dioxide, disintegrants such as starch and sodium alginate, magnesium stearate Lubricants such as talc, binders such as polyvinyl alcohol, hydroxypropyl cellulose, gelatin, casein, glycerin fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, emulsifiers such as saponin, lecithin, guar gum, alginic acid, carrageenan, agar , Pectin, gum arabic, and thickeners such as crystalline cellulose, and plasticizers such as glycerin. As the tablet form, tablets and capsules are preferable because they are easy to ingest.

The present invention will be described in detail in the following examples and formulation examples, but the present invention is not limited thereto.

[Example 1] Visual recognition operation improvement test (test method)
Ten people who met the selection criteria were taken as panels and 3 soft capsules were ingested daily for 4 weeks immediately after dinner. The visual reaction time was measured three times on day 0, day 14 and day 28 in total.
(Selection criteria) Subjects who met the following selection criteria were taken as subjects.
(1) A person who is engaged in daily VDT work and whose average usage time per day is 6.9 hours (4 to 12 hours). (2) Age 22-28 years (average age 24.6 years). (3) People who are not taking medicines and health foods at all times. (4) A person who can observe the matters to be observed and receive medical examinations stipulated in the test method.

(Sample) Soft capsule 100 mg of soft capsule skin (gelatin 75% by weight, glycerin 25% by weight) is filled with 160 mg of medium chain fatty acid glyceride and 40 mg of astaxanthin-containing oil as a capsule content by a conventional method. Got. Astaxanthin-containing oil is an extract produced from Haematococcus algae containing 5% by weight of astaxanthin in terms of free form.

(Visual reaction time measurement method-follow-up test)
The visual reaction time was measured in the dark room, and the subject's head movement was prevented using a chin rest and bite board.
Computers were used to create stimuli and control experiments and measure reaction time, and stimuli were presented on a monitor. The stimulus on the monitor (see FIG. 1) was presented at a distance of 27 cm in front of the subject, and the subject observed the stimulus with only a single eye. A red gaze stimulus (×), a circular frame (both luminances 1.7 cd / m2), and a white light spot (luminance 7.5 cd / m2) were presented on a black background (luminance 0.13 cd / m2). The size of the gaze stimulus was 0.8 ° × 0.8 °, the size of the circular frame was 0.8 ° in diameter, and the center-to-center distance from the gaze stimulus was 5 ° in the horizontal direction. The size of the light spot is 0.37 ° in diameter, and is shown at the center of one of the circular frames. The stimulus moved left and right at a rate of 10 ° / s.
At the beginning of each trial, a gaze stimulus and a circular frame were presented stationary at a position 10 ° to the right or left in the horizontal direction from the center of the screen, and then moved back and forth a distance of 20 ° centered on the center of the screen 300 ms later. Light spots were presented at random time points of 1000 to 3000 ms from the start of reciprocal movement. The subject follows the center circle accurately, and when the light spot appears, the reaction button corresponding to the position of the light spot is pushed, and the time interval from the presentation of the light spot until the reaction button is pushed is measured as the reaction time. did.
The subject was subjected to 50 trials after dark adaptation for 5 minutes, and then this trial was performed. Each trial interval was 2000 ms. A total of 10 blocks (500 trials in total) were performed with 50 trials as one block. The gaze stimulus and the circle movement start position (right or left from the center of the screen) were always the same position in the block, but the position where the light spot was presented was random. The interval between each block was 1 minute. Subject was given a 1-minute break when one block was completed. The time required to perform one task was approximately 90 minutes.
Trials with a reaction time of 100 ms or less or 1000 ms or more, trials that blinked when the target was presented, trials that did not follow were excluded from the analysis, and only the valid reaction time was used for the analysis (all trials in all blocks) The average reaction time for each block (50 trials) was calculated.
During the test, using an eye movement measuring device (NAC EMR-8), it was confirmed that the subject was following the gaze stimulus accurately.

(Measurement method of visual reaction time-control test)
In the follow-up trial, the visual reaction time was measured in the same manner as in the follow-up trial, except that the gaze stimulus and the circular frame were stationary and presented in the center of the screen, and then a light spot was presented. A control test was conducted one block before and after 10 blocks of the follow-up trial.

ｐ＜０．０５（ｔ−ｔｅｓｔ、０日目 ｖｓ １４日目、０日目 ｖｓ ２８日目）、単位はｍｓ [Table 1] Results of visual response time measurement in follow-up test

p <0.05 (t-test, day 0 vs. day 14, day 0 vs. day 28), unit ms

ｐ＜０．０５（ｔ−ｔｅｓｔ、０日目 ｖｓ １４日目、０日目 ｖｓ ２８日目）、単位はｍｓ [Table 2] Results of visual response time measurement in the control test

p <0.05 (t-test, day 0 vs. day 14, day 0 vs. day 28), unit ms

In the same day test of the follow-up trial, the reaction time was fast in the block immediately after the start, and the reaction time became slower as the number of blocks increased. The reaction time gradually decreased as the astaxanthin intake period increased. In control trials performed before and after 10 follow-up trials, there was no difference depending on the astaxanthin intake period.
Control trials that did not require eye tracking of the target were ineffective, and tracking trials that required eye tracking of the target showed improvement. Astaxanthin administration has shown accurate visual information recognition and corresponding improvements in operation.

[Production Example 1] Tablet According to a conventional method, the following ingredients were uniformly mixed and tableted at the following composition ratio (% by weight) to give a tablet of 300 mg per tablet.
Asteryl powder 100 parts by weight Lactose 5 parts by weight Potato starch 12 parts by weight Polyvinyl alcohol 2 parts by weight Magnesium stearate 1 part by weight Asteryl powder (manufactured by Fuji Chemical Industry Co., Ltd.) contains 1% by weight of astaxanthin in terms of free form It is a powder produced from Haematococcus alga extract oil.

[Production Example 2] Intraoral rapidly disintegrating tablet The following ingredients were uniformly mixed and tableted in the following composition ratio (% by weight) according to a conventional method to obtain a tablet of 300 mg per tablet.
Asterel powder 50 parts by weight F-MELT 39 parts by weight Rice starch 10 parts by weight Magnesium stearate 1 part by weight F-MELT (manufactured by Fuji Chemical Industry Co., Ltd.) It is a dosage form.

[Formulation Example 3] Drink agent The following ingredients were blended, and water was added to 10 L according to a conventional method to prepare a drink agent.
Water-soluble astaxanthin solution 50g
Liquid sugar 1000g
DL-sodium tartrate 1g
Citric acid 10g
Vitamin C 10g
Vitamin E 20g
25 g of cyclodextrin
Potassium chloride 2g
Magnesium sulfate 1g
A water-soluble astaxanthin solution [manufactured by Fuji Chemical Industry Co., Ltd.] is obtained by making an aqueous solution of Haematococcus alga extract oil containing 0.5% by weight of astaxanthin in terms of free form.

  According to the present invention, a cognitive motor function improving agent composed of xanthophyll and a food or drink having an effect of improving cognitive motor function disorder composed of xanthophyll can be provided. This composition consisting of xanthophyll improves human recognition and response movement more effectively, so that recognition and response movement are impaired, i.e. dementia, injury, aging change It improves the state in which the response movement is reduced, and improves the cognitive / reaction movement ability, so that it is possible to perform accurate and accurate movements in sports and other competitions.

The example of the monitor display of a visual reaction time measuring device is shown. X indicates a red attention stimulus, ○ indicates a white circle, and ◎ indicates a white light spot. The background is black. The average reaction time for each block is shown. Blocks 1 to 10 on the horizontal axis indicate the number of blocks in the follow-up test, block 11 indicates a block before the control test, and block 12 indicates a block after the control test.

Claims (7)

Cognitive motor function improving / enhancing composition comprising xanthophyll. The composition according to claim 1 containing 2 to 100 mg of xanthophyll. The composition according to any one of claims 1 to 2, wherein a mixing ratio of xanthophyll and fatty acid glyceride is 4 to 30:40 to 90. The composition according to any one of claims 1 to 3, wherein the xanthophyll is astaxanthin. The composition according to any one of claims 1 to 4, wherein the recognition is visual recognition (visual recognition). Foods and drinks, functional foods, and pharmaceuticals containing the composition according to any one of claims 1 to 5. The use method of the xanthophyll for manufacturing the visual motor function improvement and improvement composition of any one of Claims 1-5.

Images